Literature DB >> 26530626

The CYP1A2 -163C > A polymorphism is associated with super-refractory schizophrenia.

Rodrigo Bernini de Brito1, Leandro de Carvalho Araújo2, Mateus José Abdalla Diniz3, Raphaela de Castro Georg4, João Carlos Nabout5, Rosana Pereira Vianelo4, Rodrigo da Silva Santos4, Aline Helena da Silva Cruz4, Paulo César Ghedini6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26530626     DOI： 10.1016/j.schres.2015.10.018

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  5 in total

Review 1.  Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics.

Authors:  John Lally; Fiona Gaughran; Philip Timms; Sarah R Curran
Journal:  Pharmgenomics Pers Med       Date:  2016-11-07

Review 2.  Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis.

Authors:  Shusuke Numata; Hidehiro Umehara; Tetsuro Ohmori; Ryota Hashimoto
Journal:  Front Pharmacol       Date:  2018-09-26       Impact factor: 5.810

3.  The CYP2C19*2 and CYP2C19*17 Polymorphisms Influence Responses to Clozapine for the Treatment of Schizophrenia.

Authors:  Christielly Rodrigues-Silva; Agostinho Tavares Semedo; Hiasmin Franciely da Silva Neri; Rosana Pereira Vianello; Carlos Galaviz-Hernández; Martha Sosa-Macías; Rodrigo Bernini de Brito; Paulo César Ghedini
Journal:  Neuropsychiatr Dis Treat       Date:  2020-02-11       Impact factor: 2.570

4.  The effect of CYP1A2 gene polymorphism on the metabolism of theophylline.

Authors:  Shijuan Xiong; Lingling Li
Journal:  Exp Ther Med       Date:  2017-10-30       Impact factor: 2.447

5.  Association of CYP19A1 and CYP1A2 genetic polymorphisms with type 2 diabetes mellitus risk in the Chinese Han population.

Authors:  Yafeng Yang; Ping Wang
Journal:  Lipids Health Dis       Date:  2020-08-19       Impact factor: 3.876
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.